Pharmaceutical Industries Ltd.
Your browser does not support iframes.
See Teva's sites around the world
Japan & S. Korea
Bosnia & Herzegovina
Want to find out more about Teva's locations and phone numbers?
Visit Teva Worldwide
Board of Directors
2016 Annual Report on Form 20-F
Notice of Annual Meeting of Shareholders 2017 – Proxy Statement
Over the Counter (OTC)
Central Nervous System (CNS)
Teva at IATI BIOMED 2015
Leading the Fight for Cures
National Network of Excellence
Position on Antimicrobial Resistance (AMR)
2016 Social Impact Report
Previous CSR Reports
Supplier Code of Conduct & Information for Our Suppliers
Global Patient Organization and Advocacy Disclosure
Teva Fact Sheet
Four New Independent Directors Join the Teva Board
Webcasts and Presentations
Grow with the Best
Our Guiding Values
Grow with the Best
Go to Parent
Transforming Knowledge into Treatments
Our dedicated researchers are focused on improving patient health through the application of the most up-to-date and innovative research technology and techniques.
Share on Facebook
Share on LinkedIn
We are working on:
Understanding the molecular mechanisms underpinning disease
Applying new technology in an innovative and thoughtful manner
Generating personalized medicine and pharmacogenomics hypotheses early to incorporate into clinical studies
Leveraging collaboration and partnership to capitalize on cutting-edge science
Developing Exceptional Medicines
Our R&D group has an exceptional track record in translating early drug opportunities into clinically-proven drug candidates. Key medicines we have brought to market include Copaxone® and Azilect®.
How We Do It
Our specialty R&D work ranges from the discovery and validation of new therapeutic targets and compounds, preclinical studies (including toxicology, pharmacokinetics, pharmacodynamics and pharmacology studies) to clinical pharmacology and the design, execution and analysis of clinical trials. We conduct these activities for both small molecules and biologics. In addition, our research and manufacturing facilities are fully equipped to support both GLP development and cGMP manufacture.
Striving for Better Every Day
Patients are at the center of all we do. Every day, we are hard at work creating medicines that will improve the quality of life and quality of care for millions of people worldwide.
You May Also Like...
Prime Minister Stephen Harper Advances Canada - Israel Relations
Research & Academic Partnerships
Croatian Prime Minister Orešković Opens Teva’s Multi-purpose Synthesis Plant in Croatia
The World's Generic Pharmaceuticals Leader